The World Health Organization does not recommend the use of weight-loss medications for children under the age of 10.

The World Health Organization (WHO) has issued a strong recommendation against the use of weight-loss medications in children under 10, stating that the long-term effects of such potent drugs on the

AASTOCKSOct 7 16:00

JPMorgan: Not overly concerned about the impact of rising interest rates on China's healthcare sector, and remains bullish on biotechnology and CXO services.

JPMorgan released a report stating that, as global interest rates—particularly the yields on 10-year and 30-year U.S. Treasuries—rise, the risk-free rate used in its DCF model and the stock valuations based on DCF are under greater pressure than before. Consequently, the firm has reassessed the potential impact of interest rates on Chinese healthcare valuations, especially within the biotechnology and CXO subsectors. If a higher risk-free rate is adopted in the DCF analysis, companies such as Insilico Medicine (03696.HK) in the AIDD space, GenScript (01548.HK) and Wuxi Apptec (02359.HK) in the CXO sector, and Junshi Biosciences (018…

AASTOCKSOct 6 10:19

Behind the Plunge in Hong Kong-Listed Innovative Drugs: An October Gamble on Global Expansion Amid a Liquidity Vacuum

On October 2, the Hong Kong stock market, fresh from a lengthy National Day holiday, delivered an unexpected stress test to investors. As a key barometer of market sentiment, the Hang Seng

businesstimes cnOct 3 07:30

PEGBIO CO-B: 2026 Interim Report

HKEXSep 23 16:49

Paige Biopharma-B (02565) proposes the appointment of Rongcheng Hong Kong as the new auditor

PaiGe Biopharmaceutical-B (02565) announced that, due to the company's failure to reach a consensus with KPMG Accounting Firm (KPMG) regarding the audit fees for the year ended December 31, 2026,

Zhitong FinanceSep 18 22:26

HK Stock Announcements Watch: China Gold International Selected for Hang Seng Growth Index and Hang Seng Stock Connect SOE Quality Index

Keymed Biosciences-B (02162) has entered into a licensing agreement for the marketing registration and commercialization of its spesolimab injection in 18 countries and regions, including Southeast Asia and Central Asia; Ketuo Shares (02272) plans to implement full circulation of its H-shares.

Zhitong FinanceSep 3 09:00